Press Releases

Date	Title
November 23, 2020	Corcept Therapeutics Appoints Gillian M. Cannon, PhD, to Board of Directors
November 18, 2020	U.S. Patent Trial and Appeals Board Affirms Validity of All Claims of Corcept’s U.S. Patent No.10,195,214
November 3, 2020	Corcept Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
October 27, 2020	Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
September 10, 2020	Corcept Therapeutics Initiates Second Phase 2 Trial of Miricorilant to Treat Weight Gain Caused by Antipsychotic Medication
August 4, 2020	Corcept Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update
July 28, 2020	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 28, 2020	Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant in Patients with Cushing’s Syndrome of Adrenal Origin
July 23, 2020	Corcept Therapeutics Completes Enrollment in Controlled, Phase 2 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Ovarian Cancer
June 30, 2020	Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer